Oxbridge Clinical

We are developing new technology that enables point-of-care, germ-specific diagnosis and antibiograms, in a fraction of current cost, time and infrastructure. While doctors can often diagnose infectious diseases clinically, there are no tools to easily identify the microorganism underlying each case: this leads to the overprescription of broad-spectrum antibiotics, contributing to antimicrobial resistance –a global emergency, projected to become the first cause of death by 2050, surpassing cancer! We received seed funding and opened a lab with very promising results, and are now pursuing our Series A.